RB1 and lung cancer: Considering that CDK4/6/Rb pathways are frequently upregulated in the lung cancer patients, CDK4/6 inhibitors are considered as a safe and effective strategy for treating lung cancer (Lim et al., 2016; Patnaik et al., 2016).